Skip to main content
NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%
TT

Trevi Therapeutics, Inc. (TRVI)

NASDAQ • Healthcare

$16.64
-$0.17 (-1.1%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$16.87
Previous Close$16.64
Day Range$16.51 - $17.02
Avg. Volume (3M)1.4M
Market Cap$2.3B
52 Week Range
$7.65$20.22
Next EarningsIn 63 daysNov 12, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$51.1M
EPS (TTM)
-$0.34
ROA (TTM)
-15.46%
Current Ratio
37.28
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+40.0%Q1 2026-$0.06
-28.6%Q2 2026-$0.09
-0.5%Q3 2026-$0.11
Next

Nov 12

in 63 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -0.5%

Trevi Therapeutics’ preliminary results for the second fiscal quarter of 2026 showed a wider year-over-year loss, with EPS coming in in line with consensus; the company reported the quarter ended June 30, 2026 on August 6, 2026. EPS was -$0.110 versus the -$0.109 estimate (difference -$0.001, in line), and was down ~22% from -$0.090 a year ago. Net income was -$17.8 million, down ~45% from -$12.3 million a year ago, while operating income stood at -$20.5 million. Cash burn remained evident, with negative operating cash flow of -$17.4 million during the quarter. Consensus for the next period calls for EPS of -$0.130.

View full earnings history

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing Haduvio for neurologically mediated conditions. The company is an early-stage healthcare business rather than a commercial drug seller, with its work centered on a single oral therapy candidate from its base in New Haven, Connecticut.

Name
Trevi Therapeutics, Inc.
CEO
Jennifer L. Good
Website
www.trevitherapeutics.com
Industry
Healthcare
Year Founded
2011
Employees
34

Today's Snapshot

AI-generated

TRVI ended yesterday 1.1% down at 16.64.

Trading Volume

Below 10d avg (1.3M)

959.5K

vs S&P 500 Today

Underperforming Market

-0.59%

Updated: September 10, 2026 at 12:06 UTC

Technical Indicators

2 Buy2 Neutral4 Sell
TRVI shows short-term weakness as the stock trades below most short- and medium-term averages while remaining above the 200-day level, and momentum indicators skew negative with a sub-50 RSI and a negative MACD. Trend strength is muted with ADX near the low-teens to high-teens, while ATR points to moderate intraday volatility of roughly 0.8, and on-balance volume is softer, suggesting limited buying interest. The price sits just under the classic pivot near 16.86, reinforcing nearby resistance. Technical takeaway: short-term bearish bias dominates despite longer-term support, consistent with a sell stance.
All signals
  • EMA (5 indicators)$14.41 - $17.43
    Sell
  • RSI (14)39.23
    Neutral
  • Stochastic %K (14, 3, 3)26.29
    Neutral
  • MACD Level (12, 26)-0.31
    Sell

Peers & Related Assets

PGENPrecigen, Inc.
$6.8-1.0%
ZBIOZenas BioPharma, Inc.
$32.29-2.3%
ZYMEZymeworks Inc.
$27.15-3.4%
NVAXNovavax, Inc.
$9.85-3.3%
ORICORIC Pharmaceuticals, Inc.
$12.5-0.9%
WVEWave Life Sciences Ltd.
$4.81-2.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.